vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Guardian Pharmacy Services, Inc. (GRDN). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $397.6M, roughly 1.2× Guardian Pharmacy Services, Inc.). Guardian Pharmacy Services, Inc. runs the higher net margin — 5.3% vs -10.1%, a 15.4% gap on every dollar of revenue.

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

CVS Pharmacy Inc. is an American retail corporation. A subsidiary of CVS Health, it is headquartered in Woonsocket, Rhode Island. Originally named the Consumer Value Stores, it was founded in Lowell, Massachusetts, in 1963.

CLOV vs GRDN — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.2× larger
CLOV
$487.7M
$397.6M
GRDN
Higher net margin
GRDN
GRDN
15.4% more per $
GRDN
5.3%
-10.1%
CLOV

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLOV
CLOV
GRDN
GRDN
Revenue
$487.7M
$397.6M
Net Profit
$-49.3M
$20.9M
Gross Margin
21.5%
Operating Margin
-10.1%
7.7%
Net Margin
-10.1%
5.3%
Revenue YoY
44.7%
Net Profit YoY
-123.2%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
GRDN
GRDN
Q4 25
$487.7M
$397.6M
Q3 25
$496.6M
$377.4M
Q2 25
$477.6M
$344.3M
Q1 25
$462.3M
$329.3M
Q4 24
$337.0M
Q3 24
$331.0M
$314.4M
Q2 24
$356.3M
Q1 24
$346.9M
Net Profit
CLOV
CLOV
GRDN
GRDN
Q4 25
$-49.3M
$20.9M
Q3 25
$-24.4M
$9.8M
Q2 25
$-10.6M
$9.0M
Q1 25
$-1.3M
$9.4M
Q4 24
$-22.1M
Q3 24
$-9.2M
$-122.0M
Q2 24
$7.4M
Q1 24
$-19.2M
Gross Margin
CLOV
CLOV
GRDN
GRDN
Q4 25
21.5%
Q3 25
19.8%
Q2 25
19.8%
Q1 25
19.5%
Q4 24
Q3 24
24.5%
19.4%
Q2 24
30.3%
Q1 24
23.6%
Operating Margin
CLOV
CLOV
GRDN
GRDN
Q4 25
-10.1%
7.7%
Q3 25
-4.9%
4.3%
Q2 25
-2.2%
3.7%
Q1 25
-0.3%
3.9%
Q4 24
-6.4%
Q3 24
-2.7%
-33.3%
Q2 24
2.0%
Q1 24
-6.5%
Net Margin
CLOV
CLOV
GRDN
GRDN
Q4 25
-10.1%
5.3%
Q3 25
-4.9%
2.6%
Q2 25
-2.2%
2.6%
Q1 25
-0.3%
2.9%
Q4 24
-6.6%
Q3 24
-2.8%
-38.8%
Q2 24
2.1%
Q1 24
-5.5%

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
GRDN
GRDN
Cash + ST InvestmentsLiquidity on hand
$78.3M
$65.6M
Total DebtLower is stronger
$0
Stockholders' EquityBook value
$308.7M
$217.9M
Total Assets
$541.0M
$412.7M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
GRDN
GRDN
Q4 25
$78.3M
$65.6M
Q3 25
$36.5M
Q2 25
$18.8M
Q1 25
$14.0M
Q4 24
$194.5M
Q3 24
$288.0M
$37.2M
Q2 24
$254.8M
Q1 24
$208.3M
Total Debt
CLOV
CLOV
GRDN
GRDN
Q4 25
$0
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$34.3M
Q2 24
Q1 24
Stockholders' Equity
CLOV
CLOV
GRDN
GRDN
Q4 25
$308.7M
$217.9M
Q3 25
$340.9M
$195.5M
Q2 25
$344.2M
$179.7M
Q1 25
$336.1M
$163.2M
Q4 24
$341.1M
Q3 24
$342.2M
$133.9M
Q2 24
$324.9M
Q1 24
$292.5M
Total Assets
CLOV
CLOV
GRDN
GRDN
Q4 25
$541.0M
$412.7M
Q3 25
$559.7M
$390.0M
Q2 25
$575.0M
$356.3M
Q1 25
$583.7M
$334.0M
Q4 24
$580.7M
Q3 24
$653.0M
$348.0M
Q2 24
$674.2M
Q1 24
$671.8M
Debt / Equity
CLOV
CLOV
GRDN
GRDN
Q4 25
0.00×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.26×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
GRDN
GRDN
Operating Cash FlowLast quarter
$-66.9M
$34.6M
Free Cash FlowOCF − Capex
$-69.0M
FCF MarginFCF / Revenue
-14.1%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
1.65×
TTM Free Cash FlowTrailing 4 quarters
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
GRDN
GRDN
Q4 25
$-66.9M
$34.6M
Q3 25
$12.1M
$28.2M
Q2 25
$5.4M
$19.9M
Q1 25
$-16.3M
$17.6M
Q4 24
$34.8M
Q3 24
$50.0M
Q2 24
$44.8M
Q1 24
$25.9M
Free Cash Flow
CLOV
CLOV
GRDN
GRDN
Q4 25
$-69.0M
Q3 25
$11.4M
$24.2M
Q2 25
$4.8M
Q1 25
$-16.5M
Q4 24
$33.3M
Q3 24
$49.6M
Q2 24
$44.4M
Q1 24
$25.5M
FCF Margin
CLOV
CLOV
GRDN
GRDN
Q4 25
-14.1%
Q3 25
2.3%
6.4%
Q2 25
1.0%
Q1 25
-3.6%
Q4 24
9.9%
Q3 24
15.0%
Q2 24
12.5%
Q1 24
7.3%
Capex Intensity
CLOV
CLOV
GRDN
GRDN
Q4 25
0.4%
Q3 25
0.1%
1.1%
Q2 25
0.1%
Q1 25
0.0%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.1%
Q1 24
0.1%
Cash Conversion
CLOV
CLOV
GRDN
GRDN
Q4 25
1.65×
Q3 25
2.87×
Q2 25
2.21×
Q1 25
1.86×
Q4 24
Q3 24
Q2 24
6.04×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons